cagkansayin
Adaptimmune (NASDAQ:ADAP) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 (TCRR).
The immunology companies announced the merger in March. After the closing Adaptimmune shareholders own around 75% of the combined company, with TCR2 shareholders owning the remaining approximately 25%.
Shares of the combined company will continue to trade on Nasdaq under Adaptimmune's symbol ADAP.
Adaptimmune plans to complete submission of its biologics license application to the FDA for its drug candidate afami-cel for the treatment of synovial sarcoma in mid-2023, the company added.
More on Adaptimmune/TCR2:
Adaptimmune, TCR2 Therapeutics set May 30 for shareholder votes on deal
Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
Adaptimmune sheds nearly 26% after strategic combination with TCR² Therapeutics; tops Q4 consensus
TCR² Therapeutics stock rise 41% after merger deal with Adaptimmune